Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01972529
Recruitment Status : Completed
First Posted : October 30, 2013
Results First Posted : February 27, 2018
Last Update Posted : February 27, 2018
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).

Condition or disease Intervention/treatment Phase
Thrombocytopenia Associated With Liver Disease Drug: avatrombopag (lower baseline platelet count) Drug: placebo (lower baseline platelet count) Drug: avatrombopag (higher baseline platelet count) Drug: placebo (higher baseline platelet count) Phase 3

Detailed Description:
This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase. The Prerandomization Phase includes one Screening Visit that will take place from Day -14 through Day -1; the Randomization Phase includes the Baseline Period, Treatment Period, and Procedure Day Period (5 to 8 days after last dose of study drug [Study Day 10 to 13]). The Follow-up Phase comprises 2 visits: 7 days post Procedure Day and 30 days after receiving the last dose of study drug. Permitted procedures include: Paracentesis; Thoracentesis; Gastrointestinal endoscopy with or without plans for biopsy, colonoscopy, polypectomy, or variceal banding; Liver biopsy; Bronchoscopy with or without plans for biopsy; Ethanol ablation therapy or chemoembolization for HCC; Vascular catheterization (including right side procedures in participants with pulmonary hypertension); Transjugular intrahepatic portosystemic shunt; Dental procedures; Renal biopsy; Biliary interventions; Nephrostomy tube placement; Radiofrequency ablation; and Laparoscopic interventions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 231 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
Actual Study Start Date : February 2014
Actual Primary Completion Date : January 26, 2017
Actual Study Completion Date : February 27, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases

Arm Intervention/treatment
Experimental: Group A (avatrombopag, lower baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
Drug: avatrombopag (lower baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets)

Placebo Comparator: Group B (placebo, lower baseline platelet count)
placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
Drug: placebo (lower baseline platelet count)
60 mg placebo (3 x 20 mg matching placebo tablets)

Experimental: Group C (avatrombopag, higher baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
Drug: avatrombopag (higher baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets)

Placebo Comparator: Group D (placebo, higher baseline platelet count)
placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
Drug: placebo (higher baseline platelet count)
40 mg placebo (2 x 20 mg matching placebo tablets)




Primary Outcome Measures :
  1. Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure [ Time Frame: Baseline (Visit 2) up to 7 days following a scheduled procedure ]
    Responders were defined as participants who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Participants with missing information due to early withdrawal or other reasons were conservatively considered as having received a transfusion in the analysis, (i.e. a Non-responder).


Secondary Outcome Measures :
  1. Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on the Scheduled Procedure Day [ Time Frame: Day 10 to Day 13 (Visit 4) ]
    Responders were defined as participants who achieved a platelet count greater than or equal to 50 x 10^9/L on the procedure day. Participants with missing a platelet count on the procedure day were conservatively considered as not achieving a platelet count of 50x10^9/L in the analysis, (i.e. Non-responders).

  2. Change From Baseline in Platelet Count on the Scheduled Procedure Day [ Time Frame: Baseline (Visit 2) to Procedure Day 10 to Day 13 (Visit 4) ]
    Last observation carried forward was used for participants with a missing platelet count on the scheduled procedure day. Platelet count was measured preprocedure and before any platelet transfusion.


Other Outcome Measures:
  1. Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After a Scheduled Procedure [ Time Frame: Baseline (Visit 2) up to 7 days post scheduled procedure ]
    The severity of bleeding events was assessed by the investigator (or appropriately delegated study site personnel) using the WHO bleeding scale. The WHO bleeding scale is a clinical investigator-assessed five-point scale with Grade 0 = No bleeding, Grade 1 = Petechial bleeding, Grade 2 = Mild blood loss (clinically significant), Grade 3 = Gross blood loss (requires transfusion (severe)), and Grade 4 = Debilitating blood loss, retinal or cerebral associated with fatality. Participants with missing information are considered as having a WHO bleeding score greater than or equal to 2 in the analysis.

  2. Number of Participants Experiencing an Adverse Event [ Time Frame: From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years ]
    Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events, including platelet transfusion-related complications; routine laboratory evaluation for hematology, serum chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); the performance of physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. Treatment-emergent adverse events (TEAEs) were defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. Treatment-related AEs were considered by the investigator to be possibly or probably related to study drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Participants greater than or equal to 18 years of age at Screening with chronic liver disease
  2. Participants who have a mean baseline platelet count of less than 50 x 10^9/L. Platelet counts must be measured on 2 separate occasions, during the Screening Period and at Baseline, and must be performed at least one day apart with neither platelet count greater than 60 x 10^9/L. The mean of these 2 platelet counts (mean baseline platelet count) will be used for entry criteria and for assignment to the low or high baseline platelet count cohort.
  3. Participants scheduled to undergo a permitted elective procedure who, in the opinion of the investigator, will require a platelet transfusion to address a risk of bleeding associated with the procedure unless there is a clinically significant increase in platelet count from baseline
  4. Model For End-stage Liver Disease (MELD) score less than or equal to 24 at Screening
  5. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to Screening
  6. Provide written informed consent
  7. Willing and able to comply with all aspects of the protocol

Exclusion Criteria

  1. Any history of arterial or venous thrombosis, including partial or complete thrombosis
  2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening
  3. Portal vein blood flow velocity rate <10 centimeters/second at Screening
  4. Hepatic encephalopathy that cannot be effectively treated
  5. Participants with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C or D
  6. Platelet transfusion or receipt of blood products containing platelets within 7 days of Screening. However packed red blood cells are permitted.
  7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil, and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg, tirofiban) within 7 days of Screening
  8. Use of erythropoietin stimulating agents within 7 days of Screening
  9. Interferon (IFN) use within 14 days of Screening
  10. Estrogen-containing hormonal contraceptive or hormone replacement therapy use within 30 days of Screening
  11. Active infection requiring systemic antibiotic therapy within 7 days of Screening. However, prophylactic use of antibiotics is permitted.
  12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
  13. Elective procedure performed prior to Visit 4 (Procedure Day)
  14. Known to be human immunodeficiency virus positive
  15. Any clinically significant acute or active bleeding (eg, gastrointestinal, central nervous system)
  16. Known history of any primary hematologic disorder (eg, immune thrombocytopenic purpura, myelodysplastic syndrome)
  17. Known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden; prothrombin G20210A; ATIII deficiency, etc.)
  18. Participants with a history of significant cardiovascular disease (eg, congestive heart failure New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, and coronary artery bypass grafting)
  19. Females of childbearing potential who have had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a progesterone-only contraceptive implant/injection, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. All females will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 1 month before dosing.
  20. Females who are lactating or pregnant at Screening or Baseline (as documented by a positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  21. Post liver transplant participants
  22. Any participant who has previously received avatrombopag
  23. Hypersensitivity to avatrombopag maleate or any of its excipients
  24. Hemoglobin levels ≤ 8.0 or ≥ 18.0 g/dL for men and > 15 for women at Screening, with hematocrit ≥ 54% for men and ≥ 45% for women
  25. Current malignancy including solid tumors and hematologic malignancies (except HCC)
  26. Any history of concomitant medical condition that, in the opinion of the investigator(s), would compromise the participant's ability to safely complete the study
  27. Currently enrolled in another clinical trial with any investigational drug or device within 30 days of Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01972529


  Hide Study Locations
Locations
Layout table for location information
United States, California
Lancaster, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Bernardino, California, United States
San Francisco, California, United States
United States, Florida
Jacksonville, Florida, United States
Palmetto Bay, Florida, United States
Tampa, Florida, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Michigan
Rochester, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
United States, New York
Bronx, New York, United States
New York, New York, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Texas
Dallas, Texas, United States
Harlingen, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Argentina
Pilar, Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Mendoza, Argentina
Australia, New South Wales
Camperdown, New South Wales, Australia
Australia, South Australia
Adelaide, South Australia, Australia
Bedford Park, South Australia, Australia
Austria
Linz, Austria
Vienna, Austria
Wien, Austria
Belgium
Bruxelles, Belgium
Leuven, Belgium
Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Sao Jose do Rio Preto, Sao Paulo, Brazil
Sao Paulo, Brazil
Canada, Ontario
London, Ontario, Canada
Toronto, Ontario, Canada
Chile
La Serena, Chile
Santiago, Chile
China, Hunan
Changsha, Hunan, China
China, Jiangsu
Nanjing, Jiangsu, China
China, Shanghai
Shanghai, Shanghai, China
China
Beijing, China
France
Strasbourg, Bas Rhin, France
Grenoble cedex 9, Isere, France
Reims, Marne, France
Clermont Ferrand cedex 1, Puy De Dome, France
Amiens cedex 1, Somme, France
Vandoeuvre les Nancy, France
Germany
Freiburg, Baden Wuerttemberg, Germany
Herne, Nordrhein Westfalen, Germany
Koeln, Nordrhein Westfalen, Germany
Kiel, Schleswig Holstein, Germany
Hamburg, Germany
Hungary
Bekescsaba, Hungary
Budapest, Hungary
Dunaujvaros, Hungary
Gyula, Hungary
Kaposvar, Hungary
Kecskemet, Hungary
Szombathely, Hungary
Zalaegerszeg, Hungary
Italy
San Giovanni Rotondo, Foggia, Italy
Bari, Italy
Bologna, Italy
Genova, Italy
Milano, Italy
Modena, Italy
Palermo, Italy
Udine, Italy
Korea, Republic of
Chuncheon, Gangwon-do, Korea, Republic of
Guri-si, Gyeonggi-do, Korea, Republic of
Seongnam-Si, Gyeonggi-do, Korea, Republic of
Suwon, Gyeonggi-do, Korea, Republic of
Yangsan, Gyeongnam, Korea, Republic of
Hwasun, Jeollanam-do, Korea, Republic of
Busan, Korea, Republic of
Daegu, Korea, Republic of
Incheon, Korea, Republic of
Seoul, Korea, Republic of
Poland
Katowice, Poland
Lodz, Poland
Myslowice, Poland
Szczecin, Poland
Wroclaw, Poland
Portugal
Coimbra, Portugal
Lisboa, Portugal
Porto, Portugal
Viana do Castelo, Portugal
Vila Real, Portugal
Viseu, Portugal
Spain
Barcelona, Spain
Pontevedra, Spain
Sevilla, Spain
Valencia, Spain
Valladolid, Spain
Taiwan
Kaohsiung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan
Taoyuan City, Taiwan
Thailand
Bangkoknoi, Bangkok, Thailand
Ratchathewi, Bangkok, Thailand
Mueang Nonthaburi, Chiang Mai, Thailand
Khlong Luang, Pathumthani, Thailand
United Kingdom
Truro, Cornwall, United Kingdom
London, Greater London, United Kingdom
Manchester, Greater Manchester, United Kingdom
Wolverhampton, West Midlands, United Kingdom
Leeds, West Yorkshire, United Kingdom
Sponsors and Collaborators
Eisai Inc.
  Study Documents (Full-Text)

Documents provided by Eisai Inc.:
Study Protocol  [PDF] December 2, 2016
Statistical Analysis Plan  [PDF] February 16, 2017


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01972529     History of Changes
Other Study ID Numbers: E5501-G000-310
2013-000965-34 ( EudraCT Number )
First Posted: October 30, 2013    Key Record Dates
Results First Posted: February 27, 2018
Last Update Posted: February 27, 2018
Last Verified: January 2018
Keywords provided by Eisai Inc.:
Thrombocytopenia
Chronic Liver Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Thrombocytopenia
Digestive System Diseases
Blood Platelet Disorders
Hematologic Diseases